Phase 3 study of AJG555 in patients with chronic constipation

Efficacy and safety trial of AJG555 in patients with chronic constipation (Phase 3 study)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223112

Enrollment

140

Registered

2016-02-24

Start date

2016-02-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic constipation

Interventions

investigational material(s) Generic name etc : AJG555 (MOVICOL) INN of investigational material : Macrogol 4000 Therapeutic category code : 235 Purgatives and clysters Dosage and Administration for In

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with chronic constipation

Exclusion criteria

Exclusion criteria: Patients with known or suspected organic constipation Patients with known or suspected symptomatic constipation or drug-induced constipation

Design outcomes

Primary

Measure	Time frame
efficacy confirmatory Frequency of Spontaneous Bowel Movement Change from baseline	—

Secondary

Measure	Time frame
efficacy Complete Spontaneous Bowel Movement SBM and CSBM Responder Rate Number of Dates to the First SBM Use of Rescue Medication Stool Consistency Measured by Bristol Stool Form Scale	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026